Key Insights• According to the research report, "Saudi Arabia Antacids Market Outlook, 2031," published by Actual Market Research, the Global Antacids Market is anticipated to add to more than 19.29 Million by 2026-31.• The baseline consumer demand for OTC antacids in Saudi Arabia is among the highest in the Middle East, driven by dietary habits (high consumption of rich, spicy foods, tea, and late-night dining) along with high rates of urban obesity. Systematic reviews and clinical meta-analyses show that the overall prevalence of Gastroesophageal Reflux Disease (GERD) symptoms in the Saudi Arabian population ranges from 28.7% to 32%, far exceeding global averages (~14%).• Traditional single-salt neutralizers (such as simple aluminum hydroxide or calcium carbonate) are increasingly yielding market share to dual-mechanism, multi-action formulations. Market innovation centers heavily on sodium alginate raft-forming barriers combined with fast-acting antacid salts (pioneered by brands like Gaviscon Double Action). These formulations react with stomach acid to form a protective physical barrier floating on top of gastric contents, effectively preventing nocturnal and postprandial reflux while neutralizing excess stomach acid.• The Saudi retail sector benefits from a highly modern, widespread distribution ecosystem governed by strict healthcare quality standards. Over-the-counter antacids and acid-reducers are distributed through a dense network of over 10,000 retail pharmacy locations nationwide (led by major chains such as Nahdi Medical Company and Al-Dawaa Pharmacies).Market Outlook• With high national prevalence of type-2 diabetes and hypertension, pharmaceutical manufacturers are pivoting toward sugar-free, low-sodium antacid line extensions tailored for health-conscious and elderly Saudi consumers. Next-generation product development is moving toward dual-action therapies that combine fast-acting acid-buffering agents with gastric probiotics to restore gut microbiome balance alongside acute acidity relief.• The market is strictly regulated by the Saudi Food and Drug Authority (SFDA) with clinical insights provided by the Saudi Gastroenterology Association (SGA), while market commercialization is led by major domestic and multinational leaders including SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corporation), Jamjoom Pharma, Tabuk Pharmaceuticals, Reckitt Benckiser (Gaviscon), Bayer, Haleon, and Sanofi.Market DynamicsDriver: Rising health awareness, lifestyle changes and digestive disordersA key driver for Saudi Arabia's antacids market is the combination of increasing health awareness, changing lifestyles and a growing prevalence of digestive complaints.

Euromonitor identifies rising health awareness, increasing digestive disorders and population growth including international visitors as important factors sustaining demand for digestive remedies. Modern lifestyle patterns, including increased dining out and food-delivery consumption, can also contribute to indigestion and heartburn-related demand. Ramadan is particularly relevant, as heavier meals and overeating during festive periods can increase short-term demand for digestive remedies.Challenge: Competition from alternative acid-reflux and digestive treatmentsThe major challenge is competition from other gastrointestinal treatments, particularly H2-receptor blockers, proton-pump inhibitors (PPIs), digestive enzymes and other digestive remedies. Consumers experiencing persistent reflux may prefer products that offer longer-lasting acid suppression rather than traditional short-acting antacids. The Saudi GERD market illustrates this competitive dynamic: while antacids were the largest segment in 2024, H2-receptor blockers were identified as the fastest-growing drug type through 2030.Trend: Digital pharmacy growth and more specialized digestive-health solutionsA major trend is the increasing role of e-commerce and online pharmacies, alongside greater specialization in digestive-health products. Euromonitor identifies pharmacies as the dominant distribution channel for digestive remedies but says e-commerce is the fastest-growing channel.

Digital access allows consumers to compare products and obtain OTC digestive treatments more conveniently. At the same time, rising use of diabetes and weight-loss medications is creating new opportunities for digestive-health products because gastrointestinal side effects can increase demand for symptom-management solutions.Procurement and Industry Impact • Saudi Arabia is increasingly emphasizing local pharmaceutical manufacturing and localization of supply chains as part of its broader industrial and Vision 2030 objectives. In December 2025, the SFDA held a Generic Drugs Conference specifically focused on empowering local pharmaceutical manufacturing, bringing together regulators, pharmaceutical companies, healthcare providers and investors. The SFDA has also emphasized the importance of regulatory frameworks and quality standards in supporting pharmaceutical manufacturing and investment.• The SFDA is actively enforcing GMP and pharmaceutical quality requirements. In July 2025, the authority suspended registration of a European pharmaceutical factory after an inspection identified critical GMP and internal quality-system violations, preventing potentially affected products from being supplied to Saudi consumers. In addition, Euromonitor reports that new SFDA health-economic guidelines introduced in 2025 are expected to increase transparency by requiring cost-effectiveness evaluations for gastrointestinal treatments and antacids.Segment AnalysisSaudi Arabia Antacids Market By Drug Class• Acid neutralizers remain closely associated with rapid, on-demand relief because they directly neutralize gastric acid already present in the stomach.

Calcium carbonate, magnesium hydroxide, aluminium hydroxide and combination mineral formulations are relevant to this segment. Their principal advantage is straightforward symptom relief for occasional heartburn, acid indigestion and post-meal discomfort, making them particularly compatible with consumer self-care.• Proton Pump Inhibitors (PPIs) occupy a more sustained acid-suppression position because they reduce gastric acid production rather than neutralizing acid already present. Their relevance is stronger for recurrent reflux and clinically established GERD. Saudi clinical practice increasingly differentiates occasional symptoms from persistent reflux requiring longer-term management, creating a distinct role for PPIs alongside rapid-relief antacids.• H2 antagonists provide an intermediate approach by reducing gastric acid secretion through H2-receptor blockade. They can appeal to consumers seeking longer symptom control than conventional antacids without immediately adopting a PPI-based regimen. Their positioning is particularly relevant for episodic acid-related symptoms and pharmacist-guided treatment.• Pro-motility agents represent a specialized segment because their primary therapeutic purpose is to improve gastrointestinal movement rather than neutralize or suppress acid.

They may be relevant when reflux-like symptoms coexist with delayed gastric emptying, early satiety or post-meal fullness. Consequently, these products are more closely associated with clinically directed gastrointestinal treatment than routine antacid self-care.• Combination formulations are important because consumers may experience heartburn together with gas, bloating or acid regurgitation. Antacid-alginate combinations can provide both acid neutralization and a physical reflux barrier, while antacid-plus-simethicone formulations can address gas-related discomfort. Multi-symptom products offer manufacturers an opportunity to differentiate in a competitive gastrointestinal self-care category.Saudi Arabia Antacids Market By Dosage Form• Tablets and chewables are particularly suitable for Saudi consumers seeking convenient, portable symptom relief. Chewable tablets eliminate the need for water and can be taken after meals or while travelling. Their clearly defined unit dose also simplifies consumer use and pharmacist recommendation.• Liquid suspensions provide an important alternative for consumers who prefer liquid administration or have difficulty swallowing tablets.

Aluminium- and magnesium-based liquids can accommodate multiple active ingredients and provide flexible formulation options. Flavour, viscosity, shaking requirements and accurate measuring are important factors influencing consumer acceptance.• Powders provide a convenient single-dose format when packaged in sachets and can be designed for dissolution or dispersion before administration. Their portability makes them useful for consumers who want to carry gastrointestinal medicines outside the home. However, preparation requirements make them somewhat less convenient than ready-to-use liquids and chewables.• Gels and syrups offer smooth administration and can be particularly suitable for reflux-barrier formulations. Alginate-containing gels can create a floating physical barrier over gastric contents, providing a mechanism beyond simple acid neutralization. Syrup formulations can also differentiate through flavour and ease of swallowing.• Gummies and other formats represent an emerging consumer-oriented opportunity.

Gummies can provide a familiar, portable administration experience, but conventional antacid ingredients may be difficult to incorporate at effective quantities without compromising taste or texture. Effervescent and rapidly dispersible formats therefore offer alternative opportunities for convenience-focused product development.Saudi Arabia Antacids Market By Indication• Gastroesophageal Reflux Disease (GERD) is an important indication supporting Saudi Arabia's acid-control category. A Saudi population-based study conducted in Riyadh found GERD symptoms in 15.7% of participants, demonstrating a substantial reflux-related symptom burden. The same study found that symptoms were associated with several lifestyle and dietary factors, reinforcing the relevance of both consumer self-care and clinical management. • Heartburn is a strong consumer-facing indication because it is easily recognized and can lead to direct self-treatment. The Riyadh study reported 12.5% prevalence of heartburn, while acid regurgitation was reported by 14.7% of participants. These symptoms create demand for rapid-relief antacids as well as longer-acting acid-suppressive medicines when symptoms become recurrent.• Peptic ulcer represents a more clinically managed indication than routine heartburn.

Antacids may temporarily reduce acid-related discomfort, but appropriate treatment requires attention to underlying causes such as H. pylori infection and NSAID-associated mucosal damage. PPIs consequently have a stronger role in ulcer-healing regimens, while traditional antacids are mainly positioned around symptomatic relief.• Others include dyspepsia, acid indigestion, gastritis-related discomfort, bloating and post-meal fullness. These symptoms can overlap substantially with reflux, making consumer interpretation of acidity broader than a formal GERD diagnosis. A Saudi study of dyspepsia in primary care reported that 41.7% of surveyed patients had dyspepsia, illustrating the importance of broader upper-GI symptoms within the Saudi treatment environment. Saudi Arabia Antacids Market By Distribution Channel• Retail pharmacies remain strategically important because they provide consumers with direct access to non-prescription gastrointestinal products and pharmacist guidance. This channel is particularly relevant when consumers need help distinguishing occasional heartburn from recurrent symptoms that may require physician assessment or a longer-acting acid suppressant.• Hospital pharmacies serve a more clinically supervised segment involving patients diagnosed with GERD, peptic ulcers, gastritis and other gastrointestinal disorders. Demand through this channel is therefore influenced by physician diagnosis, hospital treatment protocols and formulary decisions rather than spontaneous OTC purchases.• Online pharmacies / E-commerce provide convenience for repeat purchases and enable consumers to compare brands, dosage forms and pack sizes.

The channel can be particularly attractive for consumers who already know which gastrointestinal product they prefer. Saudi Arabia's digital-health infrastructure and increasing use of electronic healthcare services provide a supportive environment for digitally enabled medicine purchasing, although medicine sales remain subject to regulatory requirements.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Antacids Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Drug Class• Acid Neutralizers• Proton Pump Inhibitors (PPIs)• H2 Antagonists• Pro-Motility Agents• Combination FormulationsBy Dosage Form• Tablets & Chewables• Liquid Suspensions• Powders• Gels & Syrups• Gummies & OtherBy Indication• Gastroesophageal Reflux Disease• Heartburn• Peptic Ulcer• OthersBy Distribution Channel• Retail Pharmacies• Hospital Pharmacies• Online Pharmacies / E-Commerce.